Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deoxyribonuclease 1 like 2 (DNASE1L2) is an intracellular endonuclease and member of the Dnase1 family of enzymes, classified within the broader DNase superfamily[1][2][5]. It catalyzes the hydrolysis of DNA by cleaving phosphodiester bonds, contributing to the degradation of nuclear DNA primarily during keratinocyte differentiation in the skin[1]. This activity is crucial for the removal of nuclear material during cornification and the formation of the skin barrier[1]. DNASE1L2 is conserved in amniotes and, unlike other Dnase1 family members that are secreted, its principal action is intracellular[1][5]. The enzyme is predicted to be activated following organelle disruption, allowing it access to nuclear DNA, although detailed mechanisms of escape from the endoplasmic reticulum or lysosome remain unclear[1]. DNASE1L2 does not appear to be a common direct therapeutic target and there are no reported drugs or biomarkers associated specifically with this enzyme[4][5]. Its dysfunction or altered expression may contribute to skin disorders associated with abnormal DNA degradation[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deoxyribonuclease 1 like 2 (DNASE1L2).